Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Harris Associates has disclosed a sizable stake in Zimmer Biomet Holdings, Inc. common stock. Through Harris Associates L.P. and Harris Associates, Inc., the firm reports beneficial ownership of 12,264,703 shares, representing 6.2% of Zimmer Biomet’s common stock.
Harris reports sole voting power over 11,892,571 shares and sole dispositive power over 12,264,703 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Zimmer Biomet.
Yi Sang reported open-market sale transactions in a Form 4 filing for ZBH. The filing lists transactions totaling 1,000 shares at a weighted average price of $96.49 per share. Following the reported transactions, holdings were 17,670 shares.
A shareholder of ZBH has filed a notice of proposed sale of restricted securities under Rule 144. The filing covers 1,000 shares of common stock, with an aggregate market value of 96,490.00, to be sold through Fidelity Brokerage Services LLC on the NYSE around February 12, 2026.
The shares were originally acquired from the issuer on March 6, 2024 through restricted stock vesting as part of compensation, rather than a cash purchase. By signing the notice, the seller represents that they are not aware of any material adverse, non-public information about the issuer’s current or prospective operations.
Zimmer Biomet reported solid 2025 growth with mixed earnings trends and new capital return plans. Fourth quarter net sales were $2.244 billion, up 10.9% reported and 5.4% on an organic constant currency basis. Full-year net sales reached $8.232 billion, an increase of 7.2% reported and 3.9% on an organic constant currency basis.
GAAP diluted EPS fell to $0.70 in the quarter, down 41.7%, and to $3.55 for the year, down 19.9%, largely reflecting higher costs and charges. Adjusted diluted EPS was $2.42 for the quarter, up 4.8%, and $8.20 for the year, up 2.5%. The company generated $1.697 billion in operating cash flow and $1.172 billion of free cash flow in 2025.
The Board authorized a new $1.5 billion stock repurchase program with no expiration date, after completing $250 million of buybacks in the fourth quarter. For 2026, Zimmer Biomet guides to reported revenue growth of 2.5%–4.5%, organic constant currency growth of 1.0%–3.0%, and adjusted diluted EPS of $8.30–$8.45, as it shifts toward a more direct and specialized U.S. sales model.
Zimmer Biomet Holdings, Inc. reported that Mark Bezjak, who was identified as a named executive officer in the company’s 2025 proxy statement, has informed the company he will resign his employment. His resignation, including all officer positions with Zimmer Biomet and its affiliates, will be effective January 16, 2026 so he can pursue another business opportunity.
The company previously disclosed that Mr. Bezjak ceased to be an executive officer of Zimmer Biomet as of July 1, 2025, so this filing formalizes his departure from remaining roles with the organization.
Zimmer Biomet Holdings, Inc. director Louis Shapiro reported a routine equity-related transaction involving deferred compensation. On 12/31/2025, he acquired 152.22 phantom stock units tied to Zimmer Biomet common stock under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible into one share of common stock, and the units are scheduled to be settled in company shares within sixty days after he ceases serving as a director. Following this transaction, he beneficially owned 2,500.354 phantom stock units, which includes 5.625 units previously accrued on 10/31/2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Arthur J. Higgins reported changes in his deferred compensation holdings. On 12/31/2025 he acquired 304.439 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors, which are tied 1-for-1 to shares of common stock. These units are scheduled to be settled in cash in ten annual installments after his service as a director ends, beginning within sixty days after the end of the calendar year in which his board service ceases.
Following this transaction, Higgins beneficially owned 35,967.099 phantom stock units. This total includes 85.437 phantom stock units that were previously accrued on October 31, 2025 under the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Theresa Maria Hilado reported a change in her deferred compensation holdings tied to company stock. On 12/31/2025 she acquired 373.63 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 conversion rate with common stock. Following this transaction, she beneficially owned 11,275.465 phantom stock units.
The phantom stock units are to be settled in cash in ten annual installments, beginning within sixty days after the end of the calendar year in which her service as a director ends. The reported balance includes 26.117 phantom units accrued on 10/31/2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Devdatt Kurdikar reported an equity-related transaction on 12/31/2025 under a deferred compensation arrangement. The filing shows the acquisition of 152.22 phantom stock units at a listed conversion or exercise price of $90.33, bringing his total directly held phantom stock units to 1,769.983.
The units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and are designed to be settled in shares of Zimmer Biomet common stock on a 1-for-1 basis within sixty days after he ceases serving as a director. The total includes 3.876 phantom stock units that were added on October 31, 2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings director reports phantom stock unit grant. On 12/31/2025, a company director acquired 172.977 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. These units are tied 1-for-1 to shares of Zimmer Biomet common stock and are scheduled to be settled in company shares within sixty days after the director’s service on the board ends. Following this transaction, the director beneficially owned a total of 5,579.523 phantom stock units, which includes 12.952 units accrued on 10/31/2025 through the plan’s dividend reinvestment feature.